Company intelligence / Profile preview

Oxytone Bioscience

Schijndel, Noord-Brabant, Netherlandsadis.springer.com ↗

Ownership: Private
Development stage: Other

Overview

Oxytone Bioscience develops heat-stable orally disintegrating and intravenous formulations of oxytocin for the prevention and treatment of postpartum haemorrhage. The company’s lead asset reached early clinical development but Phase I trials were terminated due to protocol issues. As of late 2021/early 2022, there have been no recent reports indicating further advancement into later-stage trials. In April 2025, the company received a $1.59 million grant from the Gates Foundation to support work in maternal and child health—likely related to its oxytocin program.

Therapeutic areas: Women's Health
Modalities: Small moleculePeptideTablet formulationIntravenous formulation
Industry: Biotech

Partnerships

Gates Foundation (grant funding partnership)

Beyond the preview

Go deeper on Oxytone Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oxytone Bioscience.

Explore the full profile